enGene Holdings Inc.
NASDAQ:ENGNBiotechnology
Healthcare
$1.85 -1.15%
-$0.02 today
- Market cap
- $123.98M
- Beta
- -0.29
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.95
52W Low $1.40High $12.25
Volume 2.81M
Average 1.58M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$99.24M
FY 2025 · Annual
Investing Cash Flow
-$25.14M
FY 2025 · Annual
Financing Cash Flow
$1.52M
FY 2025 · Annual
-99.4% YoYCash Flow Statement
USD
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Net Income | (23.44M) | (24.46M) | (99.92M) | (55.14M) | (117.3M) |
| Depreciation & Amortization | 272K | 238K | 175K | 323K | 509K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 435K | 116K | 3.45M | 5.32M | 9.65M |
| Change in Working Capital | (1.04M) | 2.17M | (517K) | 95K | 9.74M |
| Accounts Receivables | 295K | 143K | (1.01M) | 2.01M | (595K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 110K | (197K) | 373K | 474K | 4.94M |
| Other Working Capital | (1.44M) | 2.23M | 117K | (2.39M) | 5.39M |
| Other Non-Cash Items | 7.79M | 4.34M | 72.07M | 1.12M | (1.83M) |
| Operating Cash Flow | (15.98M) | (17.59M) | (24.74M) | (48.28M) | (99.24M) |
| Capital Expenditures | (248K) | (153K) | (318K) | (925K) | (1.49M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (125.03M) | (160.84M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 137.19M |
| Other Investing Activities | 1K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (247K) | (153K) | (318K) | (125.95M) | (25.14M) |
| Debt Repayment | 7.07M | 28.39M | 33.27M | 13.06M | (699K) |
| Common Stock Issued | 14K | 12K | 56.89M | 260.15M | 2.22M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (144K) | (423K) | (4.01M) | (7.49M) | 0 |
| Financing Cash Flow | 22.53M | 27.97M | 86.15M | 265.72M | 1.52M |
| Effect of Forex Changes | 98K | (805K) | 1K | 1K | 1K |
| Net Change in Cash | 6.39M | 9.42M | 61.09M | 91.48M | (122.85M) |
| Free Cash Flow | (16.23M) | (17.75M) | (25.06M) | (49.21M) | (100.72M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$117.3M
+ D&A$509.0K
+ Stock-Based Comp$9.6M
+ Deferred Tax$0
+ Working Capital$9.7M
- Other Non-Cash-$1.8M
= Operating Cash Flow-$99.2M
- Capex-$1.5M
= Free Cash Flow-$100.7M
Analysis
FY2025 free cash flow is -$100.7M. FCF conversion is 85.9% of net income. Operating cash flow was -$99.2M, with capex of -$1.5M. The largest bridge item is Working Capital at $9.7M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 3 | Initial statement of beneficial ownership | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 24, 2026 |
Does ENGN generate free cash flow?
enGene Holdings Inc. (ENGN) generated -$100.72M of free cash flow in fiscal 2025.
How much operating cash flow does ENGN produce?
Operating cash flow was -$99.24M, before capital expenditures of $1.49M.
Continue the stock analysis
Jump to another research area for this company.